Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.

Bhakta S, Crocker LM, Chen Y, Hazen M, Schutten MM, Li D, Kuijl C, Ohri R, Zhong F, Poon KA, Go MAT, Cheng E, Piskol R, Firestein R, Fourie-O'Donohue A, Kozak KR, Raab H, Hongo JA, Sampath D, Dennis MS, Scheller RH, Polakis P, Junutula JR.

Mol Cancer Ther. 2019 Nov;18(11):2182. doi: 10.1158/1535-7163.MCT-19-0749. No abstract available.

PMID:
31676543
2.

Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo.

Su D, Chen J, Cosino E, Dela Cruz-Chuh J, Davis H, Del Rosario G, Figueroa I, Goon L, He J, Kamath AV, Kaur S, Kozak KR, Lau J, Lee D, Lee MV, Leipold D, Liu L, Liu P, Lu GL, Nelson C, Ng C, Pillow TH, Polakis P, Polson AG, Rowntree RK, Saad O, Safina B, Stagg NJ, Tercel M, Vandlen R, Vollmar BS, Wai J, Wang T, Wei B, Xu K, Xue J, Xu Z, Yan G, Yao H, Yu SF, Zhang D, Zhong F, Dragovich PS.

Bioconjug Chem. 2019 May 15;30(5):1356-1370. doi: 10.1021/acs.bioconjchem.9b00133. Epub 2019 Apr 22.

PMID:
30966735
3.

High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.

Ohri R, Bhakta S, Fourie-O'Donohue A, Dela Cruz-Chuh J, Tsai SP, Cook R, Wei B, Ng C, Wong AW, Bos AB, Farahi F, Bhakta J, Pillow TH, Raab H, Vandlen R, Polakis P, Liu Y, Erickson H, Junutula JR, Kozak KR.

Bioconjug Chem. 2018 Feb 21;29(2):473-485. doi: 10.1021/acs.bioconjchem.7b00791. Epub 2018 Feb 9.

PMID:
29425028
4.

An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.

Bhakta S, Crocker LM, Chen Y, Hazen M, Schutten MM, Li D, Kuijl C, Ohri R, Zhong F, Poon KA, Go MAT, Cheng E, Piskol R, Firestein R, Fourie-O'Donohue A, Kozak KR, Raab H, Hongo JA, Sampath D, Dennis MS, Scheller RH, Polakis P, Junutula JR.

Mol Cancer Ther. 2018 Mar;17(3):638-649. doi: 10.1158/1535-7163.MCT-17-0813. Epub 2017 Dec 27. Erratum in: Mol Cancer Ther. 2019 Nov;18(11):2182.

5.

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.

Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, Lau J, Yee S, He J, Liu L, Ng C, Xu K, Leipold DD, Kamath AV, Zhang D, Masterson L, Gregson SJ, Howard PW, Fang F, Chen J, Gunzner-Toste J, Kozak KK, Spencer S, Polakis P, Polson AG, Flygare JA, Junutula JR.

Mol Cancer Ther. 2017 May;16(5):871-878. doi: 10.1158/1535-7163.MCT-16-0641. Epub 2017 Feb 21.

6.

Severe anal pain · perianal swelling · no history of injury to the area · Dx?

Galanakis CG, Bouzakis I, Polakis P.

J Fam Pract. 2016 Jan;65(1):39-40. No abstract available.

PMID:
26845163
7.

Antibody Drug Conjugates for Cancer Therapy.

Polakis P.

Pharmacol Rev. 2016 Jan;68(1):3-19. doi: 10.1124/pr.114.009373. Review.

PMID:
26589413
8.

Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer.

Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, Yu SF, Yee S, Goldenberg D, Fields C, Eastham-Anderson J, Singh M, Vij R, Hongo JA, Firestein R, Schutten M, Flagella K, Polakis P, Polson AG.

Sci Transl Med. 2015 Nov 18;7(314):314ra186. doi: 10.1126/scitranslmed.aac7433.

PMID:
26582901
9.

Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.

Lin K, Rubinfeld B, Zhang C, Firestein R, Harstad E, Roth L, Tsai SP, Schutten M, Xu K, Hristopoulos M, Polakis P.

Clin Cancer Res. 2015 Nov 15;21(22):5139-50. doi: 10.1158/1078-0432.CCR-14-3383. Epub 2015 Jul 8.

10.

An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.

Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, Desai R, Raja R, Friedman BA, Haverty PM, Polakis P, Firestein R.

Clin Cancer Res. 2015 Jul 15;21(14):3252-62. doi: 10.1158/1078-0432.CCR-15-0156. Epub 2015 Apr 10.

11.

An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.

Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D, Ohri R, Raab H, Hass PE, Pham T, Firestein R, Li D, Schutten M, Stagg NJ, Ogasawara A, Koppada N, Roth L, Williams SP, Lee BC, Chalouni C, Peng I, DeVoss J, Tremayne J, Polakis P, Polson AG.

Mol Pharm. 2015 Jun 1;12(6):1717-29. doi: 10.1021/mp5007745. Epub 2015 Apr 23.

PMID:
25853436
12.

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.

Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, Polakis P, Flygare J, Polson AG.

Clin Cancer Res. 2015 Jul 15;21(14):3298-306. doi: 10.1158/1078-0432.CCR-14-2035. Epub 2015 Apr 3.

13.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR.

J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18.

PMID:
25191794
14.

Evolutionary divergence in the catalytic activity of the CAM-1, ROR1 and ROR2 kinase domains.

Bainbridge TW, DeAlmeida VI, Izrael-Tomasevic A, Chalouni C, Pan B, Goldsmith J, Schoen AP, Quiñones GA, Kelly R, Lill JR, Sandoval W, Costa M, Polakis P, Arnott D, Rubinfeld B, Ernst JA.

PLoS One. 2014 Jul 16;9(7):e102695. doi: 10.1371/journal.pone.0102695. eCollection 2014.

15.

MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.

Asundi J, Lacap JA, Clark S, Nannini M, Roth L, Polakis P.

Mol Cancer Ther. 2014 Jun;13(6):1599-610. doi: 10.1158/1535-7163.MCT-13-0446. Epub 2014 Mar 20.

16.

Site-specific antibody drug conjugates for cancer therapy.

Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR.

MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022. Review.

17.

An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins.

Hazen M, Bhakta S, Vij R, Randle S, Kallop D, Chiang V, Hötzel I, Jaiswal BS, Ervin KE, Li B, Weimer RM, Polakis P, Scheller RH, Junutula JR, Hongo JA.

MAbs. 2014 Jan-Feb;6(1):95-107.

18.

A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.

Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, Polakis P, Holsworth DD, Krauss S, Costa M.

Cancer Res. 2013 May 15;73(10):3132-44. doi: 10.1158/0008-5472.CAN-12-4562. Epub 2013 Mar 28.

19.

Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt signaling.

Huang X, McGann JC, Liu BY, Hannoush RN, Lill JR, Pham V, Newton K, Kakunda M, Liu J, Yu C, Hymowitz SG, Hongo JA, Wynshaw-Boris A, Polakis P, Harland RM, Dixit VM.

Science. 2013 Mar 22;339(6126):1441-5. doi: 10.1126/science.1232253. Epub 2013 Jan 31.

20.

HectD1 E3 ligase modifies adenomatous polyposis coli (APC) with polyubiquitin to promote the APC-axin interaction.

Tran H, Bustos D, Yeh R, Rubinfeld B, Lam C, Shriver S, Zilberleyb I, Lee MW, Phu L, Sarkar AA, Zohn IE, Wertz IE, Kirkpatrick DS, Polakis P.

J Biol Chem. 2013 Feb 8;288(6):3753-67. doi: 10.1074/jbc.M112.415240. Epub 2012 Dec 31.

21.

An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.

Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, Stainton S, Ulufatu S, Fourie A, Kozak KR, Fuji R, Polakis P, Khawli LA, Lin K.

Br J Pharmacol. 2013 Jan;168(2):445-57. doi: 10.1111/j.1476-5381.2012.02138.x.

22.

Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.

Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, Polakis P, Khawli LA, Lin K.

J Nucl Med. 2012 Sep;53(9):1454-61. doi: 10.2967/jnumed.112.103168. Epub 2012 Aug 7.

23.
24.

Drugging Wnt signalling in cancer.

Polakis P.

EMBO J. 2012 Jun 13;31(12):2737-46. doi: 10.1038/emboj.2012.126. Epub 2012 May 22. Review. Erratum in: EMBO J. 2012 Aug;31(15):3375.

25.

The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma.

Chen Y, Chalouni C, Tan C, Clark R, Venook R, Ohri R, Raab H, Firestein R, Mallet W, Polakis P.

J Biol Chem. 2012 Jul 13;287(29):24082-91. doi: 10.1074/jbc.M112.361485. Epub 2012 May 21.

26.

Wnt signaling in cancer.

Polakis P.

Cold Spring Harb Perspect Biol. 2012 May 1;4(5). pii: a008052. doi: 10.1101/cshperspect.a008052. Review.

27.

Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5.

Liu BY, Soloviev I, Huang X, Chang P, Ernst JA, Polakis P, Sakanaka C.

Cancer Res. 2012 Mar 15;72(6):1568-78. doi: 10.1158/0008-5472.CAN-11-3668. Epub 2012 Feb 3.

28.

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR.

Nat Biotechnol. 2012 Jan 22;30(2):184-9. doi: 10.1038/nbt.2108.

PMID:
22267010
29.

Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling.

Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, Liu PS, Bheddah S, Tao J, Lill JR, Hongo JA, Davis D, Kirkpatrick DS, Polakis P, Costa M.

PLoS One. 2011;6(7):e22595. doi: 10.1371/journal.pone.0022595. Epub 2011 Jul 25.

30.

An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma.

Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, Luis E, Tien J, Firestein R, Polakis P.

Clin Cancer Res. 2011 Mar 1;17(5):965-75. doi: 10.1158/1078-0432.CCR-10-2340. Epub 2011 Jan 18.

31.

Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies.

Gong Y, Bourhis E, Chiu C, Stawicki S, DeAlmeida VI, Liu BY, Phamluong K, Cao TC, Carano RA, Ernst JA, Solloway M, Rubinfeld B, Hannoush RN, Wu Y, Polakis P, Costa M.

PLoS One. 2010 Sep 13;5(9):e12682. doi: 10.1371/journal.pone.0012682.

32.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

33.

Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells.

Liu BY, Soloviev I, Chang P, Lee J, Huang X, Zhong C, Ferrara N, Polakis P, Sakanaka C.

PLoS One. 2010 Jan 19;5(1):e8611. doi: 10.1371/journal.pone.0008611.

34.

Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.

Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, van Bruggen N, Koeppen H.

J Pathol. 2009 Jul;218(3):380-90. doi: 10.1002/path.2545.

PMID:
19334050
35.

Formation of the blood-brain barrier: Wnt signaling seals the deal.

Polakis P.

J Cell Biol. 2008 Nov 3;183(3):371-3. doi: 10.1083/jcb.200810040. Epub 2008 Oct 27.

36.

Liposomal packaging generates Wnt protein with in vivo biological activity.

Morrell NT, Leucht P, Zhao L, Kim JB, ten Berge D, Ponnusamy K, Carre AL, Dudek H, Zachlederova M, McElhaney M, Brunton S, Gunzner J, Callow M, Polakis P, Costa M, Zhang XM, Helms JA, Nusse R.

PLoS One. 2008 Aug 13;3(8):e2930. doi: 10.1371/journal.pone.0002930.

37.

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W.

Nat Biotechnol. 2008 Aug;26(8):925-32. doi: 10.1038/nbt.1480. Epub 2008 Jul 20.

PMID:
18641636
38.

Regulation of epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt signaling.

Wang BE, Wang XD, Ernst JA, Polakis P, Gao WQ.

PLoS One. 2008 May 14;3(5):e2186. doi: 10.1371/journal.pone.0002186.

39.

The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo.

DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B.

Cancer Res. 2007 Jun 1;67(11):5371-9.

40.

Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.

Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, Luis E, Zhong F, Bheddah S, Koeppen H, Gogineni A, Ross S, Polakis P, Mallet W.

Cancer Res. 2007 May 15;67(10):4924-32. Erratum in: Cancer Res. 2007 Jun 15;67(12):5998. Ross, Sarajane [added].

41.

The many ways of Wnt in cancer.

Polakis P.

Curr Opin Genet Dev. 2007 Feb;17(1):45-51. Review.

PMID:
17208432
42.

Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer.

Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, Sakanaka C.

Oncogene. 2006 Jul 20;25(31):4361-9. Epub 2006 Mar 13.

PMID:
16532032
43.

Identification and immunotherapeutic targeting of antigens induced by chemotherapy.

Rubinfeld B, Upadhyay A, Clark SL, Fong SE, Smith V, Koeppen H, Ross S, Polakis P.

Nat Biotechnol. 2006 Feb;24(2):205-9. Epub 2006 Jan 29.

PMID:
16444269
44.

A role for Hath1, a bHLH transcription factor, in colon adenocarcinoma.

Leow CC, Polakis P, Gao WQ.

Ann N Y Acad Sci. 2005 Nov;1059:174-83. Review.

PMID:
16382053
45.

EphB2 is a prognostic factor in colorectal cancer.

Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P, Koeppen H.

Clin Cancer Res. 2005 Jul 15;11(14):5181-7.

46.

Arming antibodies for cancer therapy.

Polakis P.

Curr Opin Pharmacol. 2005 Aug;5(4):382-7. Review.

PMID:
15951239
47.

Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells.

Leow CC, Romero MS, Ross S, Polakis P, Gao WQ.

Cancer Res. 2004 Sep 1;64(17):6050-7.

48.

GEPIS--quantitative gene expression profiling in normal and cancer tissues.

Zhang Y, Eberhard DA, Frantz GD, Dowd P, Wu TD, Zhou Y, Watanabe C, Luoh SM, Polakis P, Hillan KJ, Wood WI, Zhang Z.

Bioinformatics. 2004 Oct 12;20(15):2390-8. Epub 2004 Apr 8.

PMID:
15073007
49.

EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer.

Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, Chui C, Franz G, Senter P, Koeppen H, Polakis P.

Cancer Res. 2004 Feb 1;64(3):781-8.

50.

A blockade in Wnt signaling is activated following the differentiation of F9 teratocarcinoma cells.

Shibamoto S, Winer J, Williams M, Polakis P.

Exp Cell Res. 2004 Jan 1;292(1):11-20.

PMID:
14720502

Supplemental Content

Loading ...
Support Center